Trial Profile
A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2020
Price :
$35
*
At a glance
- Drugs AG 86893 (Primary)
- Indications Ocular hyperaemia; Pterygium
- Focus Therapeutic Use
- Acronyms SURPH
- Sponsors Allgenesis Biotherapeutics
- 06 Jan 2020 Status changed from active, no longer recruiting to completed.
- 15 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
- 15 Aug 2019 Status changed from recruiting to active, no longer recruiting.